AstraZeneca's RESOLUTE Trial Meets Primary Endpoint

TL;DR

AZN's SCCA trial RESOLUTE hits PFS endpoint, good news for cancer patients.

AI Summary

AstraZeneca PLC announced an update on its RESOLUTE Phase III trial for its investigational medicine, Zynyz (retifanlimab-dlwr), in combination with chemotherapy, for the first-line treatment of metastatic or unresectable unresectable locally advanced squamous cell carcinoma of the anal canal (SCCA). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus chemotherapy. Full results are expected to be presented at an upcoming medical congress.

Why It Matters

This positive outcome for the RESOLUTE trial could lead to a new first-line treatment option for SCCA patients, potentially improving their progression-free survival.

Risk Assessment

Risk Level: medium — While the trial met its primary endpoint, regulatory approval and market adoption are not guaranteed, and further clinical data and competitor developments could impact future success.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Zynyz (retifanlimab-dlwr) (drug) — Investigational medicine
• RESOLUTE (trial) — Phase III trial name
• squamous cell carcinoma of the anal canal (SCCA) (disease) — Indication being studied

FAQ

From the Filing

0001654954-25-010845.txt : 20250917 0001654954-25-010845.hdr.sgml : 20250917 20250917071152 ACCESSION NUMBER: 0001654954-25-010845 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250917 FILED AS OF DATE: 20250917 DATE AS OF CHANGE: 20250917 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251318780 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a6048z.htm UPDATE ON RESOLUTE PHASE III TRIAL a6048z FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of September 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________             AstraZeneca PLC   INDEX TO EXHIBITS     1. Update on RESOLUTE Phase III trial       17 September 2025   Update on the RESOLUTE Phase III trial for   Fasenra   in chronic obstructive pulmonary disease   The RESOLUTE Phase III trial of AstraZeneca's  Fasenra  (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic obstructive pulmonary disease (COPD). [i]   Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "COPD, which remains a leading cause of death worldwide, is a complex, heterogeneous disease and we continue to advance other promising approaches in our pipeline to address the unmet needs of patients. With its well-established ability to target and eliminate eosinophils,  Fasenra  has helped transform treatment of severe asthma, and more recently has demonstrated a significant effect in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome."   The safety and tolerability profile for  Fasenra  in the trial was consistent with the known profile of the medicine. 1  The Company will analyse the full data set from RESOLUTE to further understand the results, which will be shared with the scientific community in the future.   Fasenra  is currently approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in more than 80 countries, including the US, Japan, EU and China. 2-5 &